Applications of 2-Chloroadenine in Industrial Manufacturing

As a committed producer of 2-Chloroadenine, we support specialized industries by supplying this purine compound for well-defined downstream applications. Our customers in advanced fine chemical, pharmaceutical, and agricultural sectors integrate this material at formulation and synthesis stages according to regulatory and process-specific requirements. Below we outline key professional use cases, with emphasis on real-world compliance, process strategy, usage range, and end-product categories.

1. Antiviral Active Pharmaceutical Ingredient Synthesis

Producers in the pharmaceutical sector employ 2-Chloroadenine as a critical nucleobase intermediate when manufacturing certain prodrug antivirals. This compound enters custom synthetic routes for purine-modified nucleoside analogues. Suppliers choose 2-Chloroadenine for its suitability in high-yield stepwise condensation, meeting regulatory controls for residual solvents and batch traceability. Dosing depends on the specific nucleoside target and scale-up volume, with loading adjusted during the heterocycle assembly phase. API manufacturers require strict adherence to global pharmacopoeial standards and validated cGMP protocols for batch release.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP, Ph. Eur., JP monographs (API-related specifications)
• US FDA 21 CFR Part 211 (Finished Pharmaceuticals)
• EU EudraLex Vol 4 (GMP guidelines for APIs)

Typical usage ratio

• Used at 1.0-1.5 molar equivalents in the nucleoside coupling step, adjusted to match targeted reaction yield and downstream impurity profiles.

Downstream process integration

• Incorporated as a nucleobase in the early chemical synthesis stages for custom antiviral APIs, reacting with glycosyl donors in protected or unprotected form under microwave or solution-phase conditions.

Final product types

• Oral and parenteral antiviral pharmaceuticals (e.g., modified guanosine or adenosine analogues for treatment of viral infections)

2. Plant Growth Regulator Intermediate Manufacturing

Manufacturers in the agrochemical sector utilize 2-Chloroadenine as a precursor for synthesis of cytokinins and related plant growth regulators. Its purine structure enables high selectivity during alkylation or amination, yielding cytokinin molecules for commercial plant tissue culture and foliar application products. Downstream processors demand material that meets both agricultural regulatory checks and synthetic suitability, with adjustments based on conversion efficiency. Compliance hinges on residue analysis, traceability, and permitted additive thresholds according to national and international agrochemical legislation.

Industry compliance standards

• FAO/WHO Codex Alimentarius (Pesticide Residue Limits)
• EU Regulation (EC) No 1107/2009 (authorization of plant protection products)
• US EPA 40 CFR Part 180 (Pesticide Tolerances)
• China GB 2763-2021 (MRL standards for pesticides)

Typical usage ratio

• Acts as a main substrate at 0.5–1.1 molar equivalents per targeted cytokinin batch, adjusted for reaction conversion and desired active content.

Downstream process integration

• Fed into batch reactors for nucleophilic substitution or amination steps, leading to active cytokinin intermediates used in synthesized or bioformulated agrochemicals.

Final product types

• Cytokinin technicals (e.g., kinetin analogues), plant tissue culture reagents, water-soluble plant growth regulator solutions and wettable powders

3. Fine Chemical Custom Synthesis for Research Applications

Contract research organizations (CROs) and specialty chemical developers procure 2-Chloroadenine to serve as a building block in laboratory-scale syntheses of modified nucleosides, fluorescent probes, or ligands. Sourcing requires analytical-grade consistency and detailed COA documentation. Technicians calculate batchwise molar ratios to control pathway selectivity and product isolation. Compliance centers on lab safety, documentation, and chemical inventory traceability under local hazardous materials regulations and international material transfer agreements.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• ISO 9001:2015 (Quality Management Systems for laboratories)
• Local chemical storage and use legislation (e.g., US OSHA 29 CFR 1910.1200)
• REACH Regulation (EC) No 1907/2006 (for chemical substances in research)

Typical usage ratio

• Variable: generally 0.2–2.0 molar equivalents, adapted for targeted synthesis (probe labeling, ligand construction) and scale (mg to gram quantities).

Downstream process integration

• Dissolved in anhydrous solvents or aqueous mineral acids as an input for stepwise synthesis or derivatization in automated or manual laboratory setups; closely controlled during the purine-modification stage.

Final product types

• Custom nucleosides, labeled genetic probes, synthetic ligands for screening libraries, and bioconjugation intermediates

4. Diagnostic Enzyme Substrate Manufacturing

Producers in the clinical diagnostics sector apply 2-Chloroadenine as a precursor for synthesizing enzyme substrates and reporter molecules. Enzyme activity assays based on modified purines depend on high-purity material, with formulation tailored for water solubility and stability. Quality assurance includes compliance with biomedical quality systems, and end users verify incoming raw material identity and contaminant profiles using validated analytical methods. Ingredient loading varies depending on product format and the required substrate concentration.

Industry compliance standards

• ISO 13485:2016 (Medical Devices – QMS for IVD manufacturers)
• US FDA 21 CFR Part 820 (Quality System Regulation)
• IVDR (EU 2017/746, for in vitro diagnostic medical devices)
• CLSI GP44-A4 (Procedures for Preparation and Testing of Reagent Water in Clinical Laboratories)

Typical usage ratio

• Incorporated at 0.1–0.8 mg/mL, depending on final assay sensitivity requirements and shelf-life targets for substrate solutions or dry blends.

Downstream process integration

• Introduced in precursor synthesis for enzymatic diagnostic kits, either via direct chemical derivatization or as part of nucleoside-based label assembly, prior to formulation as test reagents or standards for clinical analyzers.

Final product types

• Enzyme substrate solutions for bioassays, chromogenic or fluorogenic diagnostic reagents, IVD kit components, and calibration standards for clinical laboratories